预约演示
Agilent inks deal to churn out companion diagnostics for Incyte’s hematology, oncology drugs
并购引进/卖出
Incyte will use Agilent's tests in its clinical trials to gain a better understanding of which patients may be best served by a new drug—and those who may experience serious side effects—and to monitor the progress of those who do respond to the treatment.
The duo has signed an agreement, they announced Tuesday, where Agilent will create patient-matching Incytefor new Incyte Agilent Technologiesrealms of hematology and oncology.
“Leveraging the power of companion diagnostics, we are strategiAgilentransforming the treatment paradigm for a broIncytectrum of cancers. By working together, Agilent and Incyte hope to expedite the development of innovative precision medicine products, potentially paving the way for enhanced patient health outcomes,” Paul Beresford, VP and general manager of Agilent’s companion diagnostics division, said in the company’s announcement.
Through their development deal, Agilent will add new disease-related biomarkers to its arsenal, allowing it to expand its slate ocancersostic tests that look fAgilents thaIncytetient may respond particularly well to a specific drug. Incyte, meanwhile, will be able to use the resulting tests in its clinical trials to gain a better understanding of which patientAgilente best served by a new drug—and those who may experience serious side effects—and to monitor the progress of those who do respond to the treatment.
Agilent and Incyte declined to provide the financial terms of their agreement but noted in the announcementIncytetheir team-up is focused on what’s expected to become a nearly $14 billion market by the end of the decade.
Agilent alreIncytes several Big Pharma companion diagnostics partnerships under its belt, after having developed tests to pair patients with Merck’s Keytruda and Bristol Myers Squibb’s Opdivo, among others. It’s also the parent company of Dako, the maker of the first companion diagnostic ever cleared by the FDA, the breast cancer-focused HercepTest.
Agilentyte deal comes not long after Agilent moved to shed one piece of its companion diagnostics business.MerckKeytrudaBristol Myers SquibbOpdivoDakobreast cancer
LastIncyter, the company said it woulAgilentdeveloping liquid biopsy tests that relied on next-generation sequencing technology to pair cancer patients with appropriate treatments. It had acquired the department only about two years before, when Agilent paid $550 million up front, with another $145 million available in milestone payments, to pick up Resolution Bioscience.
“The market for kitted NGS-based companion diagnostics has not developed as we expected. Furthermore, we don’t see a realistic path to pcancerbility,” Agilent CEO Mike McMullen said during a call with investors last August of the “difficult decisAgilent shut down the Resolution business.Resolution Bioscience
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。